FiercePharma

AbbVie Receives Orphan Drug Designation for HUMIRA® (adalimumab) from the U.S. Food and Drug Administration for the Investigational Treatment of Moderate-to-Severe ...

- Orphan Drug Designation program provides orphan status to medications intended for the safe and effective treatment, diagnosis or prevention of rare diseases - HS, a chronic, immune-mediated skin ...
Yahoo

UnitedHealth to remove AbbVie's Humira from some US drug reimbursement lists next year

(Reuters) - UnitedHealth Group said on Tuesday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement as of Jan. 1, 2025, and ...
Monthly Prescribing Reference

FDA Designates Yuflyma an Interchangeable Biosimilar to Humira

Credit: Celltrion. Yuflyma, a tumor necrosis factor blocker, was approved in May 2023 as a biosimilar to Humira. Similar PK, efficacy, safety, and immunogenicity data were observed between the ...
Stockhouse

AbbVie's HUMIRA® (adalimumab) Receives U.S. Food and Drug Administration Approval to Treat Adults with Non-Infectious Intermediate, Posterior and Panuveitis

NORTH CHICAGO, Ill., June 30, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved HUMIRA® ...
FiercePharma

AbbVie Receives Orphan Drug Designation for HUMIRA(R) (adalimumab) from the U.S. Food and Drug Administration for the Investigational Treatment of Certain Forms of Non ...

AbbVie Receives Orphan Drug Designation for HUMIRA(R) (adalimumab) from the U.S. Food and Drug Administration for the Investigational Treatment of Certain Forms of Non-infectious Uveitis NORTH CHICAGO ...